PPIDT00008
Drug Information
| Name | Peginterferon alfa-2a |
|---|---|
| Sequence | CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE |
| DrugBank_ID | DB00008 |
| Type | biotech |
| Indication | Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
135 mcg
|
| Injection | Subcutaneous |
180 mcg
|
| Injection, solution | Subcutaneous |
135 ug
|
| Injection, solution | Subcutaneous |
135 MCG
|
| Injection, solution | Subcutaneous |
135 ug/0.5mL
|
| Injection, solution | Subcutaneous |
180 ug/1mL
|
| Injection, solution | Subcutaneous |
180 ug/0.5mL
|
| Injection, solution | Subcutaneous |
180 mcg/ml
|
| Injection, solution | Subcutaneous |
180 ug
|
| Injection, solution | Subcutaneous |
180 MCG
|
| Injection, solution | Subcutaneous |
90 ug
|
| Solution | Subcutaneous |
0.135 mg
|
| Solution | Subcutaneous |
180 mcg / mL
|
| Solution | Subcutaneous |
180 mcg / 0.5 mL
|
| Injection | Subcutaneous |
135 mcg/0.5ml
|
| Injection | Subcutaneous |
180 mcg/0.5ml
|
| Solution; tablet | Oral; Subcutaneous |
|
| Injection, solution | Subcutaneous |
135 mcg/0.5ml
|
| Injection, solution | Subcutaneous |
180 mcg/0.5ml
|
Target Information